Silvia Pomella

Via Montpellier 1
Rome, 00133, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma.

Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma.

Journal: International journal of molecular sciences
Published: June 01, 2026

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

Journal: British journal of cancer
Published: February 04, 2026

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Journal: Cancers
Published: January 29, 2026

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.

Journal: Frontiers in cell and developmental biology
Published: December 23, 2025

Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas.

Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas.

Journal: International journal of molecular sciences
Published: November 28, 2025

Lactate-mediated NK cell dysfunction as a prognostic marker and therapeutic target in breast cancer.

Lactate-mediated NK cell dysfunction as a prognostic marker and therapeutic target in breast cancer.

Journal: Cell death discovery
Published: November 10, 2025

Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies.

Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies.

Journal: Drug discovery today
Published: August 19, 2025

Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo.

Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo.

Journal: Cell death & disease
Published: July 11, 2025

The HIV Protease Inhibitor Ritonavir Reverts the Mesenchymal Phenotype Induced by Inflammatory Cytokines in Normal and Tumor Oral Keratinocytes to an Epithelial One, Increasing the Radiosensitivity of Tumor Oral Keratinocytes.

The HIV Protease Inhibitor Ritonavir Reverts the Mesenchymal Phenotype Induced by Inflammatory Cytokines in Normal and Tumor Oral Keratinocytes to an Epithelial One, Increasing the Radiosensitivity of Tumor Oral Keratinocytes.

Journal: Cancers
Published: June 24, 2025

Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcoma.

Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcoma.

Journal: Cell death discovery
Published: April 18, 2025

Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.

Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.

Journal: Journal of hematology & oncology
Published: July 11, 2024

Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies.

Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies.

Journal: International journal of molecular sciences
Published: June 28, 2024
Showing 1-12 of 51

Last Updated: 09/26/2026